Thymosin alpha-1 research
What PubMed holds on Thymosin alpha-1, sorted by study design: the papers this site relies on, every clinical-trial publication PubMed tags, and the newest additions.
- PubMed records
- 622
- Trial publications
- 5639 randomized
- Reviews
- 85
- Human-subject tagged
- 374
- Animal-only
- 185
- Clinical-trial publications 56
- Reviews 85
- Animal-only studies 185
- Other (in vitro, chemistry, commentary, unindexed) 296
Studies this site relies on
Ordered by strength of design. Conclusions are quoted verbatim from each abstract as indexed by PubMed; read the full paper before relying on any of them.
-
Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis
Yang YF, Zhao W, Zhong YD, et al.
These data showed that compared with IFNalpha, the benefit of Talpha1 was not immediately significant at the end of therapy, but virological, biochemical and complete response had a tendency to increase or accumulate gradually after the therapy. For three of the four trials that studied HBeAg-negative patients, the results are mostly …
-
The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial
Wu J, Pei F, Zhou L, et al.
This trial found no clear evidence to suggest that thymosin α1 decreases 28 day all cause mortality in adults with sepsis.
-
The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial
Wu J, Zhou L, Liu J, et al.
The use of Tα1 therapy in combination with conventional medical therapies may be effective in improving clinical outcomes in a targeted population of severe sepsis.
-
The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial
Iino S, Toyota J, Kumada H, et al.
Adverse event incidence was similar in the 1.6- and 0.8-mg treatment groups. In conclusion, Talpha1 at doses of 0.8 and 1.6 mg exhibits long-term efficacy against hepatitis B with a good safety profile.
-
A Pilot Trial of Thymalfasin (Thymosin-α-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection
Shehadeh F, Benitez G, Mylona EK, et al.
Tα1 increases CD4+ T-cell count among patients with baseline low-flow oxygen support faster than the standard of care and may have a role in the management of hospitalized patients with hypoxemia and lymphocytopenia due to COVID-19.
-
Thymosin alpha 1: A comprehensive review of the literature
Dominari A, Hathaway Iii D, Pandav K, et al.
In this review, we discuss key literature on the background knowledge and current clinical uses of thymosin alpha 1. Considering the known biochemical properties including antibacterial and antiviral properties, time-honored applications, and the new promising findings regarding the use of thymosin, we believe that thymosin alpha 1 …
Clinical-trial publications in PubMed
56 records carry PubMed’s clinical-trial publication type; the 40 most recent are listed. Tagging is done by NLM indexers and occasionally includes secondary analyses.
Newest records
The most recent PubMed additions for this query at the data-edition date, regardless of design.
- Thymosin α-1 in cancer therapy: Immunomodulatory mechanisms, clinical applications, and translational perspectives Eur J Pharmacol · 2026 · Review
- Clinical Applications and Evidence Landscape of Thymosin Alpha 1 as an Immunomodulatory Adjunct in Cancer Care: A Scoping Review Pharmaceuticals (Basel) · 2026 · Review
- Thymosin Alpha-1 Provides Direct Neuroprotection by Engaging the Orexin Receptor HCRTR1 to Suppress Neuronal Necroptosis Adv Sci (Weinh) · 2026 · Primary study
- Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells Cancer Res · 2026 · Primary study
- A prospective clinical study on the effectiveness of Phellinus igniarius decoction in treating immune dysfunction in colorectal cancer patients following chemfotherapy J Tradit Complement Med · 2026 · Primary study
- Thymosin α1 Augments CD8⁺ T-Cell Activation and Reverses Exhaustion In Vitro Asian Pac J Cancer Prev · 2026 · Primary study
- IL-15 Plus Thymosin α1 Reduces Senescent Hepatic CD8(+) T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression J Gastroenterol Hepatol · 2026 · Primary study
- Preliminary results from a phase II trial of spatially fractionated radiotherapy combined with immunotherapy and anti-angiogenic therapy in patients with bulky solid tumors: early evidence of promising efficacy and favorable safety Radiat Oncol · 2026 · Phase 2 trial
- Peptide Therapies in Thyroid Health: Emerging Applications in Endocrine and Immune Modulation Integr Med (Encinitas) · 2026 · Review
- Thymalfasin combined with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: A retrospective study on efficacy, safety, and immunological function Pak J Med Sci · 2026 · Primary study